[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100466064":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":34,"responsibleParty":50,"collaborators":53,"id":59,"slug":18,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":22,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":18,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":18,"overallStatus":37,"whyStopped":18,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Karolinska Institutet","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"SPARK app","EXPERIMENTAL","Access to the SPARK app which will provide support for a healthier diet and increased physical activity as well as daily monitoring of blood glucose levels.",[13],"Behavioral: SPARK",{"label":15,"type":16,"description":17,"interventionNames":18},"Control arm","NO_INTERVENTION","Standard care i.e., the routine treatment program for GDM delivered by the care provider.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"BEHAVIORAL","SPARK","The SPARK digital platform provides support to the patient (shown as an app) as well as provides the possibility for the health care provider to review and give feedback on blood glucose levels through the care giver interface of the platform.",[9],[26],{"name":27,"affiliation":5,"role":28},"Marie Löf, Professor","PRINCIPAL_INVESTIGATOR",[30],{"name":27,"role":31,"phone":32,"phoneExt":18,"email":33},"CONTACT","+46 734 426417","marie.lof@ki.se",[35],{"facility":36,"status":37,"city":38,"state":18,"zip":39,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Maternity health care, Region Östergötland","RECRUITING","Linköping","58185","Sweden",{"type":42,"coordinates":43},"Point",[44,45],15.62157,58.41086,{"lat":45,"lon":44},[48],{"name":49,"role":31,"phone":18,"phoneExt":18,"email":18},"Caroline Lilliecreutz, MD, Associate professor",{"type":28,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Marie Löf, docent","Professor",[54,56],{"name":55,"class":6},"Region Östergötland",{"name":57,"class":58},"Linkoeping University","OTHER_GOV","100466064",false,"NCT05348863","SPARK- a Digital Platform to Improve Self-management of Gestational Diabetes","SPARK: Smart Phone App for Gestational Diabetes Patients Supporting Key Lifestyle Behaviors and Glucose Control","Inclusion Criteria:\n\n* a confirmed diagnosis of GDM detected by oral glucose tolerance test in accordance with the World Health Organization guidelines\n\nExclusion Criteria:\n\n* known pre-pregnancy diabetes\n* twin pregnancy\n* \\\u003C18 years of age\n* severe co-morbidities that would limit participation or a previously diagnosed severe psychiatric illness.",true,"FEMALE","18 Years","50 Years",{"count":70,"type":71},360,"ESTIMATED","INTERVENTIONAL",[74],"NA","Gestational diabetes mellitus (GDM) is an increasing public health challenge. Innovative, effective and scalable lifestyle interventions to support women with GDM to manage their disease and to prevent adverse obstetric and neonatal outcomes as well as later morbidity are requested.The aim of this project is to evaluate whether a novel, mobile health (mHealth) platform (SPARK) can improve self-management of GDM and prevent adverse maternal and offspring outcomes. SPARK is a multi-centre randomised controlled trial recruiting women diagnosed with GDM in South Eastern Sweden. Women will be randomised to the control or intervention group. All women will receive standard care. The intervention group will also receive support through the SPARK platform for healthy eating, physical activity and glycaemic control. Pregnancy outcomes are glycaemic control (primary), diet, physical activity, metabolic and inflammatory biomarkers in gestational week 36-37 as well as adverse obstetric and neonatal outcomes. Secondary outcomes also include cardiometabolic risk, physical activity and healthy eating behaviours one-year postpartum.",[77],"Gestational Diabetes Mellitus","2025-01-17",{"date":80,"type":81},"2025-01-22","ACTUAL",{"date":83,"type":81},"2022-10-28",{"date":85,"type":71},"2026-12-30",{"name":5,"class":6},1]